Antiphospholipid syndrome (APS) is a disorder of the immune system that increases the risk of blood clots, which can lead to recurrent miscarriages during pregnancy. Managing APS, particularly in pregnant patients, involves strategies to reduce the risk of clot formation.
The recommended treatment for pregnant women with APS and a history of recurrent pregnancy loss is a combination of low-dose Aspirin and Low Molecular Weight Heparin (LMWH). This approach aims to minimize the risk of thrombosis without significantly increasing the risk of bleeding.
The rationale for using these medications is as follows:
While prednisolone is used in some autoimmune disorders, it is not typically recommended for APS due to its side effects and insufficient evidence of efficacy in preventing pregnancy loss in this condition. Therefore, the correct and recommended treatment for a pregnant patient with APS experiencing recurrent abortions is:
Aspirin + Low molecular weight Heparin
